2011 Scrip Asia 100 - Hutchison MediPharma proves concept that China can innovate
This article was originally published in Scrip
Collaborations with big pharma, healthy venture investments and a robust pipeline make Shanghai-based Hutchison MediPharma a blueprint for Asian bioventures. CEO Dr Samantha Du discusses with Rebecca Debens deals, drug development and doing business in China. This article is part of the 2011 Scrip Asia 100.